Minerva Neurosciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NERV Nasdaq 2830 www.minervaneurosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Minerva Neurosciences, Inc.

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors - Nov 19th, 2025 6:30 am
Minerva Neurosciences: Q3 Earnings Snapshot - Nov 5th, 2025 5:40 am
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates - Nov 5th, 2025 5:30 am
Top Midday Gainers - Oct 21st, 2025 11:36 am
BC-Most Active Stocks - Oct 21st, 2025 8:30 am
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved - Oct 21st, 2025 6:00 am
Minerva Neurosciences: Q2 Earnings Snapshot - Aug 14th, 2025 2:43 pm
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results - Aug 14th, 2025 2:35 pm
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - May 13th, 2025 5:30 am
Minerva Neurosciences: Q1 Earnings Snapshot - May 13th, 2025 5:22 am
Minerva Neurosciences: Q4 Earnings Snapshot - Feb 25th, 2025 5:32 am
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates - Feb 25th, 2025 5:00 am